Methylscopolamine bromide

Identification

Name
Methylscopolamine bromide
Accession Number
DB00462  (APRD00314)
Type
Small Molecule
Groups
Approved
Description

A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors. [PubChem]

Structure
Thumb
Synonyms
  • (−)-scopolamine methobromide
  • (−)-scopolamine methyl bromide
  • Hyoscine Methobromide
  • Hyoscine methyl bromide
  • Methscopolamine bromide
  • N-methylhyoscine bromide
  • N-methylscopolammonium bromide
  • Scopolamine Methobromide
  • Scopolamine methyl bromide
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Methscopolamine BromideTablet5 mg/1OralA. Aarons2009-10-222015-12-29Us
Methscopolamine BromideTablet2.5 mg/1OralE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2011-03-16Not applicableUs
Methscopolamine BromideTablet2.5 mg/1OralA. Aarons2009-10-222015-12-29Us
Methscopolamine BromideTablet5 mg/1OralE. Fougera & CO., A division of Fougera Pharmaceuticals Inc.2011-07-27Not applicableUs
PamineTablet2.5 mg/1OralPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1953-04-092015-12-29Us
PamineTablet2.5 mg/1OralPharma Derm, A Division Of Fougera Pharmaceuticals Inc.1953-04-09Not applicableUs
Pamine ForteTablet5 mg/1OralPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2003-03-252015-12-29Us
Pamine ForteTablet5 mg/1OralPharma Derm, A Division Of Fougera Pharmaceuticals Inc.2003-03-25Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
MethscopolamineTablet5 mg/1OralGolden State Medical Supply2006-12-28Not applicableUs64376 0604 61 nlmimage10 f608fb57
Methscopolamine BromideTablet2.5 mg/1OralBreckenridge Pharmaceutical, Inc.2012-05-21Not applicableUs
Methscopolamine BromideTablet5 mg/1OralPd Rx Pharmaceuticals, Inc.2013-10-01Not applicableUs
Methscopolamine BromideTablet2.5 mg/1OralBoca Pharmacal, Inc.2006-12-28Not applicableUs
Methscopolamine BromideTablet5 mg/1OralBayshore Pharmaceuticals, LLC2013-10-01Not applicableUs
Methscopolamine BromideTablet5 mg/1OralBreckenridge Pharmaceutical, Inc.2012-05-21Not applicableUs
Methscopolamine BromideTablet5 mg/1OralBoca Pharmacal, Inc.2006-12-28Not applicableUs
Methscopolamine BromideTablet2.5 mg/1OralPd Rx Pharmaceuticals, Inc.2013-10-01Not applicableUs
Methscopolamine BromideTablet2.5 mg/1OralBayshore Pharmaceuticals, LLC2013-10-01Not applicableUs
International/Other Brands
Pamine
Categories
UNII
RTN51LK7WL
CAS number
155-41-9
Weight
Average: 398.291
Monoisotopic: 397.088870908
Chemical Formula
C18H24BrNO4
InChI Key
CXYRUNPLKGGUJF-JIRGPDKYSA-M
InChI
InChI=1S/C18H24NO4.BrH/c1-19(2)14-8-12(9-15(19)17-16(14)23-17)22-18(21)13(10-20)11-6-4-3-5-7-11;/h3-7,12-17,20H,8-10H2,1-2H3;1H/q+1;/p-1/t12?,13-,14+,15+,16?,17?;/m1./s1
IUPAC Name
(1S,5S)-7-{[(2S)-3-hydroxy-2-phenylpropanoyl]oxy}-9,9-dimethyl-3-oxa-9-azatricyclo[3.3.1.0²,⁴]nonan-9-ium bromide
SMILES
[Br-].[H][[email protected]]12C[[email protected]@H](C[[email protected]@]([H])(C3OC13)[N+]2(C)C)OC(=O)[[email protected]](CO)C1=CC=CC=C1

Pharmacology

Indication

Used as adjunctive therapy for the treatment of peptic ulcer. Also used to treat nausea and vomiting due to motion sickness.

Structured Indications
Pharmacodynamics

Methscopolamine is a muscarinic antagonist structurally similar to the neurotransmitter acetylcholine and acts by blocking the muscarinic acetylcholine receptors and is thus classified as an anticholinergic. Methscopolamine has many uses including the prevention of motion sickness. It is not clear how Methscopolamine prevents nausea and vomiting due to motion sickness. The vestibular part of the ear is very important for balance. When a person becomes disoriented due to motion, the vestibule sends a signal through nerves to the vomiting center in the brain, and vomiting occurs. Acetylcholine is a chemical that nerves use to transmit messages to each other. It is believe that Methscopolamine prevents communication between the nerves of the vestibule and the vomiting center in the brain by blocking the action of acetylcholine. Methscopolamine also may work directly on the vomiting center. Methscopolamine must be taken before the onset of motion sickness to be effective.

Mechanism of action

Methscopolamine acts by interfering with the transmission of nerve impulses by acetylcholine in the parasympathetic nervous system (specifically the vomiting center). It does so by acting as a muscarinic antagonist.

TargetActionsOrganism
AMuscarinic acetylcholine receptor M1
antagonist
Human
AMuscarinic acetylcholine receptor M2
antagonist
Human
UMuscarinic acetylcholine receptor M3
antagonist
Human
Absorption

Poorly and unreliably absorbed, total absorption is 10-25%.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Little is known about the fate and excretion of methscopolamine.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Symptoms of a methscopolamine overdose include headache, nausea, vomiting, dry mouth, difficulty swallowing, blurred vision, dilated pupils, hot, dry skin, dizziness; drowsiness, confusion, anxiety, seizures, weak pulse, and an irregular heartbeat. In addition, a curare-like action may occur, i.e., neuromuscular blockade leading to muscular weakness and possible paralysis.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AclidiniumAclidinium may increase the anticholinergic activities of Methylscopolamine bromide.Approved
AlcuroniumThe risk or severity of adverse effects can be increased when Alcuronium is combined with Methylscopolamine bromide.Experimental
AlfentanilThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Alphaprodine.Illicit
AmbenoniumThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Ambenonium.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Methylscopolamine bromide.Approved
AtracuriumThe risk or severity of adverse effects can be increased when Atracurium is combined with Methylscopolamine bromide.Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Methylscopolamine bromide.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Methylscopolamine bromide.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Methylscopolamine bromide.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Methylscopolamine bromide.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Methylscopolamine bromide.Approved
BezitramideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Methylscopolamine bromide.Approved, Investigational
BornaprineThe risk or severity of adverse effects can be increased when Bornaprine is combined with Methylscopolamine bromide.Experimental
Botulinum Toxin Type AMethylscopolamine bromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BMethylscopolamine bromide may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButorphanolThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Butorphanol.Approved, Illicit, Vet Approved
CarfentanilThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Carfentanil.Illicit, Investigational, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Methylscopolamine bromide.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Methylscopolamine bromide.Withdrawn
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Methylscopolamine bromide.Approved
CimetropiumMethylscopolamine bromide may increase the anticholinergic activities of Cimetropium.Experimental, Investigational
CodeineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Codeine.Approved, Illicit
CoumaphosThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Coumaphos.Vet Approved
CyclopenthiazideThe serum concentration of Cyclopenthiazide can be increased when it is combined with Methylscopolamine bromide.Experimental
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Methylscopolamine bromide.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Methylscopolamine bromide.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Decamethonium.Approved
DemecariumThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Demecarium.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methylscopolamine bromide.Approved, Investigational
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Methylscopolamine bromide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Dezocine.Approved, Investigational
DichlorvosThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Methylscopolamine bromide.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Dihydrocodeine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Dihydromorphine.Experimental, Illicit
DiphenoxylateThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Diphenoxylate.Approved, Illicit
DistigmineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Distigmine.Experimental
DonepezilThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Donepezil.Approved
DPDPEThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with DPDPE.Experimental
DronabinolMethylscopolamine bromide may increase the tachycardic activities of Dronabinol.Approved, Illicit
EchothiophateThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Edrophonium.Approved
EluxadolineMethylscopolamine bromide may increase the constipating activities of Eluxadoline.Approved
EmeproniumThe risk or severity of adverse effects can be increased when Emepronium is combined with Methylscopolamine bromide.Experimental
EtanautineThe risk or severity of adverse effects can be increased when Etanautine is combined with Methylscopolamine bromide.Experimental
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Methylscopolamine bromide.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Etorphine.Illicit, Vet Approved
EtybenzatropineThe risk or severity of adverse effects can be increased when Etybenzatropine is combined with Methylscopolamine bromide.Experimental
FentanylThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Methylscopolamine bromide.Approved
GalantamineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Galantamine.Approved
GallamineThe risk or severity of adverse effects can be increased when Gallamine is combined with Methylscopolamine bromide.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Methylscopolamine bromide.Approved
Glucagon recombinantThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Glucagon recombinant.Approved
GlycopyrroniumMethylscopolamine bromide may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Heroin.Approved, Illicit, Investigational
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Methylscopolamine bromide.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Methylscopolamine bromide.Approved
Huperzine AThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Methylscopolamine bromide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Methylscopolamine bromide.Approved, Investigational
HydromorphoneThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Methylscopolamine bromide.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Methylscopolamine bromide.Approved
IpidacrineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Ipidacrine.Experimental
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methylscopolamine bromide.Approved
IsoflurophateThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Isoflurophate.Approved, Investigational, Withdrawn
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Methylscopolamine bromide.Investigational
KetobemidoneThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Ketobemidone.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Levomethadyl Acetate.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Lofentanil.Illicit
MalathionThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Malathion.Approved, Investigational
MazaticolThe risk or severity of adverse effects can be increased when Mazaticol is combined with Methylscopolamine bromide.Experimental
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Methylscopolamine bromide.Approved
MefloquineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Memantine.Approved, Investigational
MeptazinolThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Meptazinol.Experimental
MethadoneThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Methylscopolamine bromide.Approved, Investigational
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Methylscopolamine bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Methylscopolamine bromide.Approved
MetoclopramideThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Metoclopramide.Approved, Investigational
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Methylscopolamine bromide.Approved
MianserinMianserin may increase the anticholinergic activities of Methylscopolamine bromide.Approved, Investigational
MinaprineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Mirabegron.Approved
MorphineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Morphine.Approved, Investigational
NabiloneMethylscopolamine bromide may increase the tachycardic activities of Nabilone.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Nalbuphine.Approved
NeostigmineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NicomorphineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Nicomorphine.Experimental
NormethadoneThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Normethadone.Approved, Illicit
OpiumThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methylscopolamine bromide.Approved
OtiloniumThe risk or severity of adverse effects can be increased when Otilonium is combined with Methylscopolamine bromide.Experimental, Investigational
OxitropiumThe risk or severity of adverse effects can be increased when Oxitropium is combined with Methylscopolamine bromide.Investigational
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Methylscopolamine bromide.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Methylscopolamine bromide.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Methylscopolamine bromide.Approved
ParaoxonThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Paraoxon.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Pentazocine.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Methylscopolamine bromide.Approved
PethidineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Pethidine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Phenazocine.Experimental
PhenglutarimideThe risk or severity of adverse effects can be increased when Phenglutarimide is combined with Methylscopolamine bromide.Experimental
PhenoperidineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Phenoperidine.Experimental
PhysostigmineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Methylscopolamine bromide.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Methylscopolamine bromide.Approved
PiritramideThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Methylscopolamine bromide.Approved
Potassium ChlorideMethylscopolamine bromide may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Methylscopolamine bromide.Approved, Investigational
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Methylscopolamine bromide.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Methylscopolamine bromide.Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Methylscopolamine bromide.Approved, Investigational
PyridostigmineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Methylscopolamine bromide.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Methylscopolamine bromide.Approved
RamosetronMethylscopolamine bromide may increase the constipating activities of Ramosetron.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Remifentanil.Approved
RivastigmineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Rivastigmine.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methylscopolamine bromide.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Methylscopolamine bromide.Approved, Vet Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Methylscopolamine bromide.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Methylscopolamine bromide.Approved
SufentanilThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Sufentanil.Approved, Investigational
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Methylscopolamine bromide.Approved, Investigational
TacrineThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Tacrine.Investigational, Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Tapentadol.Approved
TilidineThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Tilidine.Experimental
TiotropiumMethylscopolamine bromide may increase the anticholinergic activities of Tiotropium.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Methylscopolamine bromide.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Methylscopolamine bromide is combined with Tramadol.Approved, Investigational
TrichlorfonThe therapeutic efficacy of Methylscopolamine bromide can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Methylscopolamine bromide.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Methylscopolamine bromide.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Methylscopolamine bromide.Approved, Investigational
TropatepineThe risk or severity of adverse effects can be increased when Tropatepine is combined with Methylscopolamine bromide.Experimental
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Methylscopolamine bromide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Methylscopolamine bromide.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Methylscopolamine bromide.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Methylscopolamine bromide.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Methylscopolamine bromide.Approved
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB14605
KEGG Drug
D00715
PubChem Compound
23724781
PubChem Substance
46506260
ChemSpider
26329507
ChEBI
6845
Therapeutic Targets Database
DAP001126
PharmGKB
PA164784032
Wikipedia
Methylscopolamine

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
  • Nycomed us inc
  • Novartis consumer health inc
Packagers
Dosage forms
FormRouteStrength
TabletOral2.5 mg/1
TabletOral5 mg/1
Prices
Unit descriptionCostUnit
Pamine Forte 60 5 mg tablet Box234.68USD box
Transderm-Scop 1.5 mg (1 Box Contains 4 Patches)14.87USD patch
Transderm-Scop 1.5 mg (1 Box Contains 10 Patches)12.04USD patch
Transderm-scop 1.5 mg/72hr12.01USD each
Pamine fq dose pack kit2.77USD each
Pamine 2.5 mg tablet2.72USD tablet
Methscopolamine brom 5 mg tablet2.09USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)225 °CNot Available
water solubilityFreely solubleNot Available
logP-2.58Not Available
Caco2 permeability-6.16ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.0132 mg/mLALOGPS
logP-2ALOGPS
logP-3.3ChemAxon
logS-4.5ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.76 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity95.63 m3·mol-1ChemAxon
Polarizability48.12 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.8093
Blood Brain Barrier+0.6997
Caco-2 permeable+0.6465
P-glycoprotein substrateSubstrate0.5869
P-glycoprotein inhibitor INon-inhibitor0.9276
P-glycoprotein inhibitor IINon-inhibitor0.8179
Renal organic cation transporterNon-inhibitor0.5677
CYP450 2C9 substrateNon-substrate0.7319
CYP450 2D6 substrateNon-substrate0.7662
CYP450 3A4 substrateSubstrate0.6154
CYP450 1A2 substrateNon-inhibitor0.8458
CYP450 2C9 inhibitorNon-inhibitor0.8889
CYP450 2D6 inhibitorNon-inhibitor0.9036
CYP450 2C19 inhibitorNon-inhibitor0.8401
CYP450 3A4 inhibitorNon-inhibitor0.8293
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.921
Ames testNon AMES toxic0.7609
CarcinogenicityNon-carcinogens0.9189
BiodegradationNot ready biodegradable0.8731
Rat acute toxicity2.5731 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9778
hERG inhibition (predictor II)Non-inhibitor0.871
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as beta hydroxy acids and derivatives. These are compounds containing a carboxylic acid substituted with a hydroxyl group on the C3 carbon atom.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Hydroxy acids and derivatives
Sub Class
Beta hydroxy acids and derivatives
Direct Parent
Beta hydroxy acids and derivatives
Alternative Parents
Benzene and substituted derivatives / Piperidines / Morpholines / N-alkylpyrrolidines / Tetraalkylammonium salts / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Epoxides / Dialkyl ethers
show 9 more
Substituents
Beta-hydroxy acid / Monocyclic benzene moiety / Oxazinane / Piperidine / Morpholine / N-alkylpyrrolidine / Benzenoid / Tetraalkylammonium salt / Pyrrolidine / Quaternary ammonium salt
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Phosphatidylinositol phospholipase c activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM1
Uniprot ID
P11229
Uniprot Name
Muscarinic acetylcholine receptor M1
Molecular Weight
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Figueroa KW, Suga H, Ehlert FJ: Investigating the interaction of McN-A-343 with the M muscarinic receptor using its nitrogen mustard derivative and ACh mustard. Br J Pharmacol. 2010 Jul;160(6):1534-49. doi: 10.1111/j.1476-5381.2010.00810.x. [PubMed:20590642]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
G-protein coupled acetylcholine receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM2
Uniprot ID
P08172
Uniprot Name
Muscarinic acetylcholine receptor M2
Molecular Weight
51714.605 Da
References
  1. Soukup O, Proska J, Binder J, Karasova JZ, Tobin G, Jun D, Marek J, Musilek K, Fusek J, Kuca K: Methylacridinium and its cholinergic properties. Neurotox Res. 2009 Nov;16(4):372-7. doi: 10.1007/s12640-009-9071-8. Epub 2009 Jun 30. [PubMed:19565307]
  2. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor activity
Specific Function
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name
CHRM3
Uniprot ID
P20309
Uniprot Name
Muscarinic acetylcholine receptor M3
Molecular Weight
66127.445 Da
References
  1. Sykes DA, Dowling MR, Charlton SJ: Exploring the mechanism of agonist efficacy: a relationship between efficacy and agonist dissociation rate at the muscarinic M3 receptor. Mol Pharmacol. 2009 Sep;76(3):543-51. doi: 10.1124/mol.108.054452. Epub 2009 Jun 4. [PubMed:19498041]
  2. Voigtlander U, Johren K, Mohr M, Raasch A, Trankle C, Buller S, Ellis J, Holtje HD, Mohr K: Allosteric site on muscarinic acetylcholine receptors: identification of two amino acids in the muscarinic M2 receptor that account entirely for the M2/M5 subtype selectivities of some structurally diverse allosteric ligands in N-methylscopolamine-occupied receptors. Mol Pharmacol. 2003 Jul;64(1):21-31. [PubMed:12815157]
  3. Saito M, Kazuyama E, Shimizu S, Dimitriadis F, Kinoshita Y, Masuda E, Yamada S, Satoh K: Muscarinic receptors and their mRNAs in type 2 Goto-Kakizaki diabetic rat prostate. Prostate. 2010 Oct 1;70(14):1533-9. doi: 10.1002/pros.21188. [PubMed:20687226]

Drug created on June 13, 2005 07:24 / Updated on November 07, 2017 01:38